225 related articles for article (PubMed ID: 9001417)
1. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
Seymour JF; Talpaz M; Kurzrock R
Leukemia; 1997 Jan; 11(1):42-7. PubMed ID: 9001417
[TBL] [Abstract][Full Text] [Related]
2. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
[TBL] [Abstract][Full Text] [Related]
6. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
8. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
[TBL] [Abstract][Full Text] [Related]
9. Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients.
Marotta G; Frassoldati A; Zinzani P; Annino L; Brugiatelli M; Ambrosetti A; Lenoci M; Federico M; Foa R; Lauria F;
Eur J Haematol; 2006 Aug; 77(2):109-13. PubMed ID: 16856905
[TBL] [Abstract][Full Text] [Related]
10. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Ho AD; Thaler J; Mandelli F; Lauria F; Zittoun R; Willemze R; McVie G; Marmont AM; Prümmer O; Stryckmans P
J Clin Oncol; 1989 Oct; 7(10):1533-8. PubMed ID: 2789273
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia.
Habermann TM; Andersen JW; Cassileth PA; Bennett JM; Oken MM
Br J Haematol; 1992 Apr; 80(4):466-71. PubMed ID: 1581231
[TBL] [Abstract][Full Text] [Related]
12. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.
Urba WJ; Baseler MW; Kopp WC; Steis RG; Clark JW; Smith JW; Coggin DL; Longo DL
Blood; 1989 Jan; 73(1):38-46. PubMed ID: 2783373
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
14. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients.
Rafel M; Cervantes F; Beltrán JM; Zuazu F; Hernández Nieto L; Rayón C; García Talavera J; Montserrat E
Cancer; 2000 Jan; 88(2):352-7. PubMed ID: 10640967
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration.
Thaler J; Grünewald K; Gattringer C; Ho AD; Weyrer K; Dietze O; Stauder R; Fluckinger T; Lang A; Huber H
Br J Haematol; 1993 May; 84(1):75-82. PubMed ID: 8338781
[TBL] [Abstract][Full Text] [Related]
16. [Hairy cell leukemia successfully treated with 2'-deoxycoformycin following refractoriness to splenectomy and alpha-interferon therapy].
Shibata T; Hotta T
Rinsho Ketsueki; 1992 Feb; 33(2):216-20. PubMed ID: 1635172
[TBL] [Abstract][Full Text] [Related]
17. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
Saven A; Piro LD
Ann Intern Med; 1993 Aug; 119(4):278-83. PubMed ID: 8101069
[TBL] [Abstract][Full Text] [Related]
18. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.
Flinn IW; Kopecky KJ; Foucar MK; Head D; Bennett JM; Hutchison R; Corbett W; Cassileth P; Habermann T; Golomb H; Rai K; Eisenhauer E; Appelbaum F; Cheson B; Grever MR
Blood; 2000 Nov; 96(9):2981-6. PubMed ID: 11049974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
